Annexin Pharmaceuticals AB (publ) (STO:ANNX)
12.55
-0.25 (-1.95%)
Aug 13, 2026, 3:45 PM CET
Annexin Pharmaceuticals AB Employees
Annexin Pharmaceuticals AB had 4 employees as of March 31, 2026. The number of employees did not change compared to the same quarter last year.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-9.86M SEK
Market Cap
90.36M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 4 | 0 | - |
| Dec 31, 2025 | 4 | 0 | - |
| Sep 30, 2025 | 4 | 0 | - |
| Jun 30, 2025 | 4 | 0 | - |
| Mar 31, 2025 | 4 | 0 | - |
| Dec 31, 2024 | 4 | 0 | - |
| Sep 30, 2024 | 4 | 0 | - |
| Jun 30, 2024 | 4 | -1 | -20.00% |
| Mar 31, 2024 | 4 | -1 | -20.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Sep 30, 2023 | 4 | 0 | - |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | -1 | -20.00% |
| Mar 31, 2022 | 5 | 0 | - |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Nanologica AB | 72 |
| NextCell Pharma AB | 24 |
| 2cureX AB | 14 |
| Disruptive Pharma AB | 12 |
| AcouSort AB | 11 |
| Ascelia Pharma AB | 10 |
| Spago Nanomedical AB | 5 |
| Active Biotech AB | 5 |
Annexin Pharmaceuticals AB News
- 4 months ago - Annexin Pharmaceuticals AB Quarterly report: Q1 2026 - Filings
- 6 months ago - Annexin Pharmaceuticals AB Annual report: Q4 2025 - Filings
- 6 months ago - Annexin Pharmaceuticals AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Annexin Pharmaceuticals AB Transcript: Life Science Summit 2025 - Transcripts
- 10 months ago - Annexin Pharmaceuticals AB Quarterly report: Q3 2025 - Filings